Cancer Communications
indexed by SCI
BMC

doi: 10.5732/cjc.011.10188
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
Zhong-Zhen Guan, Jian-Ming Xu, Rong-Cheng Luo, Feng-Yi Feng, Li-Wei Wang, Lin Shen, Shi-Ying Yu, Yi Ba, Jun Liang, Dong Wang, Shu-Kui Qin, Jie-Jun Wang, Jing He, Chuan Qi, Rui-Hua Xu
State Key Laboratory of Oncology in South China; Department of Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China. guanzhzh@mail.sysu.edu.cn.
[Abstract] The efficacy and safety of bevacizumab with modified irinotecan, leucovorin bolus, and 5-fluorouracil intravenous infusion (mIFL) in the first-line treatment of metastatic colorectal cancer (mCRC) has not been well evaluated in randomized clinical trials in Chinese patients. We conducted a phrase III trial in which patients with previously untreated mCRC were randomized 2:1 to the mIFL [irinotecan (125 mg/m2), leucovorin (20 mg/m2) bolus, and 5-fluorouracil intravenous infusion (500 mg/m2) weekly for four weeks every six weeks] plus bevacizumab (5 mg/kg every two weeks) group and the mIFL group, respectively. Co-primary objectives were progression-free survival (PFS) and 6-month PFS rate. In total, 214 patients were enrolled. Our results showed that addition of bevacizumab to mIFL significantly improved median PFS (4.2 months in the mIFL group vs. 8.3 months in the bevacizumab plus mIFL group, P < 0.001), 6-month PFS rate (25.0% vs. 62.6%, P < 0.001), median overall survival (13.4 months vs. 18.7 months, P = 0.014), and response rate (17% vs. 35%, P = 0.013). Grades 3 and 4 adverse events included diarrhea (21% in the mIFL group and 26% in the bevacizumab plus mIFL group) and neutropenia (19% in the mIFL group and 33% in the bevacizumab plus mIFL group). No wound-healing complications or congestive heart failure occurred. Our results suggested that bevacizumab plus mIFL is effective and well tolerated as first-line treatment for Chinese patients with mCRC. Clinical benefit and safety profiles were consistent with those observed in pivotal phase III trials with mainly Caucasian patients.
Chinese Journal of Cancer 2011, Volume: 30, Issue 10, Page: 682-689
[ PDF Full-text ]
[Google Scholar]


Cite this article

Zhong-Zhen Guan, Jian-Ming Xu, Rong-Cheng Luo, Feng-Yi Feng, Li-Wei Wang, Lin Shen, Shi-Ying Yu, Yi Ba, Jun Liang, Dong Wang, Shu-Kui Qin, Jie-Jun Wang, Jing He, Chuan Qi, Rui-Hua Xu. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer. 2011, 30(10):682-689. doi:10.5732/cjc.011.10188


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CC Wechat 微信公众号

 

Editorial Manager


CC adopts Editorial Manager to manage its submissions from Dec.18, 2014
 

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CJC is now published by BioMed Central

© Chinese Journal of Cancer

Sun Yat-sen University Cancer Center

651 Dongfeng Road East, Guangzhou 510060, P. R. China